A Phase II Evaluation of Bevacizumab and Paclitaxel in Patients With Recurrent Small Cell, Large Cell, and Neuroendocrine Tumors of the Cervix and Uterus.

Trial Profile

A Phase II Evaluation of Bevacizumab and Paclitaxel in Patients With Recurrent Small Cell, Large Cell, and Neuroendocrine Tumors of the Cervix and Uterus.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Cervical cancer; Neuroendocrine tumours; Uterine cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2011 Planned end date changed from 1 Feb 2012 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 29 Jul 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Mar 2011 Planned end date changed from 1 Feb 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top